LeonaBio, Inc.
LONANext catalyst
Lasofoxifene in combination with abemaciclib
Metastatic Breast Cancer
Get an email about LONA's next catalysts
Track LeonaBio (LONA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Lasofoxifene in combination with abemaciclib Phase 3 Est. Readout (ELAINEIII)
Estimated primary completion for Lasofoxifene in combination with abemaciclib trial (NCT05696626) in Metastatic Breast Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
ATH-1017
Alzheimer Disease
IL-23 Therapy
Crohn's Disease
Lasofoxifene in combination with abemaciclib
Metastatic Breast Cancer
Amitriptyline
Quiescent Crohn's Disease (CD)
Granulocyte colony stimulating factor (GCSF)
Diabetes Mellitus, Type 1
REMD-477
Type 1 Diabetes
Pegylated GCSF
Diabetes Mellitus, Type 1
Anti-Thymocyte Globulin (ATG)
Diabetes Mellitus, Type 1
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ATH-1017 | Phase 3 | Alzheimer Disease | - | - |
IL-23 Therapy | Phase 3 | Crohn's Disease | - | - |
Lasofoxifene in combination with abemaciclib | Phase 3 | Metastatic Breast Cancer | - | - |
Amitriptyline | Phase 2 | Quiescent Crohn's Disease (CD) | - | - |
Granulocyte colony stimulating factor (GCSF) | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
REMD-477 | Phase 2 | Type 1 Diabetes | - | - |
Pegylated GCSF | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Anti-Thymocyte Globulin (ATG) | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Frequently asked questions
What is in LeonaBio, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in LeonaBio, Inc.'s (LONA) pipeline across Phase 3, Phase 2. Its lead program is Lasofoxifene in combination with abemaciclib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LeonaBio, Inc.'s next FDA catalyst?→
LeonaBio, Inc.'s (LONA) next tracked catalyst is a Phase 3 readout expected April 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LONA biotech catalysts?→
Add LONA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LeonaBio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.